Show simple item record

dc.contributor.authorGonçalves, Bianca Facchim [UNESP]
dc.contributor.authorde Campos, Silvana Gisele Pegorin [UNESP]
dc.contributor.authorFávaro, Wagner José
dc.contributor.authorBrandt, Joyce Zalotti [UNESP]
dc.contributor.authorPinho, Cristiane Figueiredo [UNESP]
dc.contributor.authorJustulin, Luis Antônio [UNESP]
dc.contributor.authorTaboga, Sebastião Roberto [UNESP]
dc.contributor.authorScarano, Wellerson Rodrigo [UNESP]
dc.date.accessioned2018-12-11T17:35:31Z
dc.date.available2018-12-11T17:35:31Z
dc.date.issued2018-01-23
dc.identifierhttp://dx.doi.org/10.1007/s12672-018-0323-z
dc.identifier.citationHormones and Cancer, p. 1-13.
dc.identifier.issn1868-8500
dc.identifier.issn1868-8497
dc.identifier.urihttp://hdl.handle.net/11449/179524
dc.description.abstractUse of drug combinations that target different pathways involved in the development and progression of prostate cancer (PCa) has emerged as an alternative to overcome the resistance caused by drug monotherapies. The antiandrogen abiraterone acetate and the PI3K/Akt inhibitor NVP-BEZ235 (BEZ235) may be suitable options for the prevention of drug resistance and the inhibition of PCa progression. The aim of the present study was to evaluate whether abiraterone acetate and BEZ235 achieve superior therapeutic effects to either drug administered as monotherapy, in the early stages of PCa in an androgen-dependent system. Our study showed that each drug might impair tumor growth by reducing proliferation and increasing cell death when administered as monotherapy. However, tumor growth continued to progress with each drug monotherapy and some important side effects were related to BEZ. Conversely, when used in combination, the drugs impaired the inflammatory response, decreased hyperplastic lesions, and blocked tumor progression from premalignant to a malignant stage. Our data showed that the strategy to block the androgenic and PI3K/AKT/mTOR pathway is an effective therapeutic option and should be investigated including distinct PI3K pathway inhibitors.en
dc.format.extent1-13
dc.language.isoeng
dc.relation.ispartofHormones and Cancer
dc.sourceScopus
dc.titleCombinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Ratsen
dc.typeArtigo
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.description.affiliationDepartment of Morphology Institute of Biosciences Sao Paulo State University (UNESP), Rua Professor Doutor Antonio Celso Wagner Zanin, 250
dc.description.affiliationInstitute of Biosciences Humanities and Exact Sciences Sao Paulo State University (UNESP)
dc.description.affiliationInstitute of Biology University of Campinas (UNICAMP)
dc.description.affiliationUnespDepartment of Morphology Institute of Biosciences Sao Paulo State University (UNESP), Rua Professor Doutor Antonio Celso Wagner Zanin, 250
dc.description.affiliationUnespInstitute of Biosciences Humanities and Exact Sciences Sao Paulo State University (UNESP)
dc.identifier.doi10.1007/s12672-018-0323-z
dc.rights.accessRightsAcesso aberto
dc.identifier.scopus2-s2.0-85040868430
dc.identifier.file2-s2.0-85040868430.pdf
dc.relation.ispartofsjr1,251
dc.relation.ispartofsjr1,251
Localize o texto completo

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record